Welcome to OncologyPRO, the home of Esmo’s educational and scientific resources.

Adding carboplatin to neoadjuvant chemotherapy improves event-free survival for triple-negative breast cancer patients

A neoadjuvant regimen of atezolizumab, cisplatin plus pemetrexed followed by maintenance therapy has been found to be tolerable for patients with resectable mesothelioma

Combining first-line chemotherapy with atezolizumab could improve outcomes for patients with nonsquamous non-small-cell lung cancer and asymptomatic brain metastases

Durvalumab given with or without tremelimumab may improve the outcomes of patients undergoing first-line treatment for metastatic non-small-cell lung cancer

Second-line lurbinectedin plus doxorubicin does not extend overall survival compared with topotecan or CAV chemotherapy for relapsed small-cell lung cancer patients

NTRK1 fusions potentially targetable with TRK inhibitors can be identified in patients with solid tumours using next-generation sequencing of circulating tumour DNA

Unilateral or bilateral mastectomy, especially when given with radiotherapy, may be associated with poorer quality of life than a breast-conserving approach in young breast cancer survivors

A global hospital-based registry sheds light on the outcomes of children and adolescents with cancer and COVID-19